How is the Pandemic Affecting MI? The Chinese Experience

ST elevation acute myocardial infarction has high mortality and morbidity rates. It is normally treated with primary PCI. The whole system has established very effective protocols to minimize ischemic time from symptom onset to definite treatment in the cath lab. 

Recomendaciones de la ACC con el nuevo coronavirus

This study reports the experience in Hong Kong since January 2020, when all emergency protocols to contain the Covid-19 pandemic were activated.

This required suspending of all non-essential visits and adjusting services both for hospitalized and ambulatory patients. 

Between January 25 and February 10 2020, there were significant changes in assistance time compared against primary PCI in the same period one year earlier. 

The most affected was time between symptom onset and first medical contact. This depends mostly on patients, who will most likely wait at home for fear of catching Covid-19.


Read also Procedural Rescheduling Criteria in the Pandemic Era.


Historically, time from symptom onset to first medical contact is approximately 82 minutes, and it extended to 318 minutes during the pandemic.

We can scarcely understand the direct impact of this pandemic on the population’s health, let alone measure its indirect impact. 

To the extended onset to first contact time, we should add the extra time needed to identify patient epidemiology, contact history, symptoms, etc. 


Read also: ECS Guidelines for COVID-19 Management.


Finally, when primary PCI is indicated, we should also add extra time for safe patient transport, which involves time for all cath lab staff to wear protective gear. 

Original Title: Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment–Elevation Myocardial Infarction Care in Hong Kong, China.

Reference: Chor-Cheung Frankie Tam et al. Circ Cardiovasc Qual Outcomes. 2020;13:e006631.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Coronary Perforations and Use of Covered Stents: Safe and Effective Long-Term Strategy?

Coronary perforations remain one of the most serious complications of percutaneous coronary intervention (PCI), especially in cases of Ellis ruptures type III. In these...

Left Main Coronary Artery Disease: Intravascular Imaging-Guided PCI vs. Coronary Artery Bypass Grafting

Multiple randomized clinical trials have demonstrated superior outcomes with coronary artery bypass grafting (CABG) vs. percutaneous coronary intervention (PCI) in patients with left main...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...